{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:15:42Z","timestamp":1784754942701,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:sec>\n                    <jats:title>\u00a0<\/jats:title>\n                    <jats:p>Fruquintinib, a targeted therapeutic agent approved in 2018 for the treatment of metastatic colorectal cancer, is gradually being applied in an expanding range of clinical settings. Given the complexities associated with real-world dosing, a comprehensive evaluation of its safety profile is essential for optimizing clinical decision-making. We conducted a retrospective pharmacovigilance study utilizing a spontaneous reporting system. Reports related to Fruquintinib were extracted through a standardized data cleaning process and cross-validated using 3 complementary signal detection algorithms: proportional reporting ratio, Bayesian confidence propagation neural network, and reporting odds ratio (ROR). This approach was employed to systematically assess the drug\u2019s safety and identify potential adverse event signals. A total of 92 statistically significant safety signals were identified from 1188 independent cases included in the analysis, corresponding to 1836 adverse event reports. The signal distribution exhibited organ system specificity, with gastrointestinal reactions being the most prevalent category. These reactions primarily manifested as typical drug-related toxicities, including diarrhea and nausea. Other notable complications included neurological, respiratory, dermatological, renal, and cardiovascular events. Important aes not mentioned in the instructions, such as bone marrow suppression (ROR\u2005=\u200511.17), peripheral neuropathy (ROR\u2005=\u20054.24) and dehydration (ROR\u2005=\u20053.98), were also discovered. This study systematically characterizes the post-marketing safety profile of Fruquintinib through a multi-algorithm synergistic analysis, confirming that its safety profile aligns with the clinically expected outcomes based on its mechanism of action. Future research should focus on analyzing drug interaction mechanisms and exploring biomarkers to develop a precise risk-benefit assessment model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048239","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:00:33Z","timestamp":1775232033000},"page":"e48239","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing signal detection of fruquintinib-associated adverse events using the FAERS database"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7442-7361","authenticated-orcid":false,"given":"Cui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chengdu Seventh People\u2019s Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3391-6217","authenticated-orcid":false,"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chengdu Seventh People\u2019s Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/cells13030245","article-title":"Update on targeted therapy and immunotherapy for metastatic colorectal cancer.","volume":"13","author":"Underwood","year":"2024","journal-title":"Cells"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s40265-018-0998-z","article-title":"Fruquintinib: first global approval.","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/13543784.2016.1161754","article-title":"Novel anti-angiogenic therapeutic strategies in colorectal cancer.","volume":"25","author":"Tampellini","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1038\/sj.onc.1203855","article-title":"Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis.","volume":"19","author":"Karkkainen","year":"2000","journal-title":"Oncogene"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/17512433.2019.1630272","article-title":"The clinical application of fruquintinib on colorectal cancer.","volume":"12","author":"Chen","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"R9-20260406","first-page":"1","article-title":"A real-world disproportionality analysis of cidofovir from the FDA Adverse Event Reporting System (FAERS) database.","author":"Liu","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"e41460","DOI":"10.1097\/MD.0000000000041460","article-title":"Adverse events of Capmatinib: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.","volume":"104","author":"Zhang","year":"2025","journal-title":"Medicine (Baltim)"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.2217\/fon-2018-0454","article-title":"Fruquintinib and its use in the treatment of metastatic colorectal cancer.","volume":"15","author":"Deng","year":"2019","journal-title":"Future Oncol"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.2147\/CMAR.S313275","article-title":"The real-world practice of fruquintinib for Chinese patients with metastatic colorectal cancer.","volume":"13","author":"Song","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"688231","DOI":"10.3389\/fonc.2021.688231","article-title":"Case report: severe rashes associated with fruquintinib in a patient with metastatic colorectal cancer.","volume":"11","author":"Shu","year":"2021","journal-title":"Front Oncol"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12882-024-03598-8","article-title":"Fruquintinib-induced renal-limited thrombotic microangiopathy: a case report.","volume":"25","author":"Zhao","year":"2024","journal-title":"BMC Nephrol"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"20220986","DOI":"10.1515\/biol-2022-0986","article-title":"Renal microangiopathy and immune complex glomerulonephritis induced by anti-tumour agents: a case report.","volume":"19","author":"Guo","year":"2024","journal-title":"Open Life Sci"},{"key":"R16-20260406","first-page":"e68203","article-title":"Fruquintinib-induced cerebellar hemorrhage in left-sided descending metastatic colorectal adenocarcinoma: a case report and risk assessment.","volume":"16","author":"Jones","year":"2024","journal-title":"Cureus"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1161\/HYPERTENSIONAHA.122.19427","article-title":"VEGF (Vascular Endothelial Growth Factor) inhibition and hypertension: does microvascular rarefaction play a role?","volume":"80","author":"le Noble","year":"2023","journal-title":"Hypertension"},{"key":"R18-20260406","first-page":"98","article-title":"Fruquintinib-associated posterior reversible encephalopathy syndrome in a patient with multiply metastatic rectal cancer.","volume":"24","author":"Ledet","year":"2025","journal-title":"Clin Colorectal Cancer"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/STROKEAHA.123.044533","article-title":"Experimental models of posterior reversible encephalopathy syndrome: a review from pathophysiology to therapeutic targets.","volume":"55","author":"Largeau","year":"2024","journal-title":"Stroke"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:01:11Z","timestamp":1775484071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":20,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048239","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}